Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting

Rhea-AI Summary

Jazz Pharmaceuticals (Nasdaq: JAZZ) announced the election of Laura Hamill to its Board of Directors at the Annual General Meeting. Ms. Hamill, a 35-year pharmaceutical industry veteran, brings extensive executive leadership and global commercial operations expertise. Shareholders also re-elected Kenneth O'Keefe and Mark Smith, while Patrick Kennedy was appointed earlier this year.

Ms. Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences and held various executive positions at Amgen Inc. She currently serves on the boards of Y-mAbs Therapeutics, BB Biotech, and Unchained Labs. The election reflects Jazz's focus on Board renewal, with five new directors appointed in the past five years. Peter Gray and Catherine Sohn have retired from the Board, which now comprises twelve directors.

Positive

• Election of Laura Hamill, bringing 35 years of pharmaceutical industry experience to the Board
• Continued focus on Board renewal with five new directors in the past five years
• Strengthened Board expertise in commercial growth and global operations

Negative

• None.

Ms. Hamill brings extensive experience and proven leadership focused on commercial growth and shareholder value

DUBLIN, July 25, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the election of a new independent director, Laura Hamill, to its Board of Directors. Ms. Hamill, a 35-year veteran of the pharmaceutical industry brings broad executive leadership and global commercial operations expertise to the company's Board. Ms. Hamill's election follows the appointment of Patrick Kennedy earlier this year and reflects Jazz's continued focus on Board renewal. At the Annual General meeting held today, shareholders not only elected Ms. Hamill and Mr. Kennedy but also re-elected Kenneth O'Keefe and Mark Smith to an additional term.

"We are delighted to welcome Laura to the Board," said Bruce Cozadd, chairperson and CEO, Jazz Pharmaceuticals. "Her extensive commercial and industry experience and well-established track record with dynamic, multi-national companies is exceptionally aligned with Jazz's focus on creating value for shareholders. I feel certain Laura's expertise will complement the capabilities of the existing Jazz Board as we aim to transform the lives of patients and their families."

Ms. Hamill most recently held the position of Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences, Inc. from 2018 to 2019. From 2002 to 2018, Ms. Hamill served in various executive management positions at Amgen Inc., including Senior Vice President, U.S. Commercial Operations, Senior Vice President, Intercontinental Region, overseeing business operations of 26 countries worldwide, Vice President, U.S. Corporate Accounts and Reimbursement, Vice President, International Marketing and Business Operations in Zug, Switzerland. Ms. Hamill currently serves on the board of directors of Y-mAbs Therapeutics Inc., BB Biotech and Unchained Labs, a privately held company.

"I am impressed by the global talent in the organization driving the strength of Jazz's business," said Ms. Hamill. "I look forward to the opportunity to work alongside my Board colleagues and the company's management to help guide the company's future growth in order to deliver sustained value to our shareholders and meaningful impact for patients."

As previously disclosed and effective today, Peter Gray and Catherine Sohn, Pharm.D., have retired from the Jazz Board, which now will be comprised of twelve directors, five of whom have been appointed in the past five years.

"I want to thank Cathy and Peter for their outstanding service and dedication to Jazz," Mr. Cozadd added. "They both have been valued members of the Jazz Board and instrumental in our transformation and continued growth. We have been grateful for their commitment and wish them well as they transition off the Board."

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases—often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Jazz Media Contact:
Kristin Bhavnani
Head of Global Strategic Brand Engagement
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

Jazz Investor Contact:
Andrea N. Flynn, Ph.D.
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
investorinfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-shareholders-elect-laura-hamill-to-the-companys-board-of-directors-at-annual-general-meeting-302206714.html

SOURCE Jazz Pharmaceuticals plc

FAQ

Who is the new Board member elected to Jazz Pharmaceuticals (JAZZ)?

Laura Hamill, a 35-year veteran of the pharmaceutical industry with extensive executive leadership and global commercial operations expertise, was elected to Jazz Pharmaceuticals' Board of Directors at the Annual General Meeting on July 25, 2024.

What is Laura Hamill's background before joining Jazz Pharmaceuticals (JAZZ) Board?

Laura Hamill previously served as Executive Vice President of Worldwide Commercial Operations at Gilead Sciences from 2018 to 2019. Prior to that, she held various executive management positions at Amgen Inc. from 2002 to 2018, including Senior Vice President of U.S. Commercial Operations and Senior Vice President of the Intercontinental Region.

How many directors are now on the Jazz Pharmaceuticals (JAZZ) Board after recent changes?

Following the election of Laura Hamill and the retirement of Peter Gray and Catherine Sohn, the Jazz Pharmaceuticals Board now comprises twelve directors, five of whom have been appointed in the past five years.

When did Jazz Pharmaceuticals (JAZZ) hold its Annual General Meeting in 2024?

Jazz Pharmaceuticals held its Annual General Meeting on July 25, 2024, where shareholders elected Laura Hamill and re-elected Kenneth O'Keefe and Mark Smith to the Board of Directors.